Clinical Impact, Reactogenicity, and Immunogenicity After the First CoronaVac Dose in Kidney Transplant Recipients
In phase-3 trial, inactivated SARS-CoV-2 vaccine (CoronaVac, Sinovac Life-Sciences, Beijing, China) was associated with 71.1% seroconversion at least 14-days after the 2nddose, showing 50.7% efficacy against symptomatic COVID-19 among healthcare workers. Currently this vaccine has been approved for emergency use in 24 countries, including Brazil, where the national vaccination program was launched on 01/Jan/2021 following the age criterion.
Kidney transplant recipients have shown 20-30% COVID-19-associated fatality rates, have been excluded in vaccine trials, and had no early priority for vaccination. Therefore, this single-center, prospective, 12-month follow-up study was designed to assess clinical impact, reactogenicity, and immunogenicity of CoronaVac.
